Table 1.

Patient Characteristics, Distribution of Known Risk Factors, and Endpoints of the Study

Group A With Inhalations (n = 227) Group B Without Inhalations (n = 155)
Age in years 
 Mean (range)  46 (16-80)  48 (17-81)  
Disease category  
 AML/MDS/CML  165 (73%)  118 (76%) 
 ALL/NHL  23 (10%)  12 (8%)  
 Auto-BMT 39 (17%)  25 (16%)  
Inadequate inclusions  8 (4%) 6 (4%)  
Risk factors for IA infections  
 Neutropenia <0.5/nL at study entry  79 (35%)  48 (31%)  
 Building reconstruction activity  49 (22%)  36 (23%)  
 Steroid comedication  29 (13%)  20 (13%)  
 Growth factor (G-CSF/GM-CSF)* 108 (48%)  54 (35%)  
Neutropenia <0.5/nL  
 Median (range)  19 (0-50)  21 (0-50) 
Days in study  
 Median (range)  27 (2-50) 28 (0-50)  
Study endpoint reached  
 Neutrophil recovery >1.0/nL  171 (75%)  120 (77%)  
 No neutrophils until day +50  28 (12%)  18 (12%)  
 No neutropenia 4 (2%)  5 (3%)  
 Death before neutrophil recovery 24 (11%)  12 (8%) 
Group A With Inhalations (n = 227) Group B Without Inhalations (n = 155)
Age in years 
 Mean (range)  46 (16-80)  48 (17-81)  
Disease category  
 AML/MDS/CML  165 (73%)  118 (76%) 
 ALL/NHL  23 (10%)  12 (8%)  
 Auto-BMT 39 (17%)  25 (16%)  
Inadequate inclusions  8 (4%) 6 (4%)  
Risk factors for IA infections  
 Neutropenia <0.5/nL at study entry  79 (35%)  48 (31%)  
 Building reconstruction activity  49 (22%)  36 (23%)  
 Steroid comedication  29 (13%)  20 (13%)  
 Growth factor (G-CSF/GM-CSF)* 108 (48%)  54 (35%)  
Neutropenia <0.5/nL  
 Median (range)  19 (0-50)  21 (0-50) 
Days in study  
 Median (range)  27 (2-50) 28 (0-50)  
Study endpoint reached  
 Neutrophil recovery >1.0/nL  171 (75%)  120 (77%)  
 No neutrophils until day +50  28 (12%)  18 (12%)  
 No neutropenia 4 (2%)  5 (3%)  
 Death before neutrophil recovery 24 (11%)  12 (8%) 
*

Probability of P < .05 for the difference between the two groups; all other comparisons between the two groups had probabilities of P > .05.

Close Modal

or Create an Account

Close Modal
Close Modal